Patient-reported outcome measures in adults with hemophilia: A scoping review
Yingrong Bai , Lulu Liu , Haode Wang , Jianglin Wang , Zhao Shi , Junchao Feng , Shunping Li
Healthcare and Rehabilitation ›› 2025, Vol. 1 ›› Issue (1) : 100007
Patient-reported outcome measures in adults with hemophilia: A scoping review
Background:Hemophilia is a generic bleeding disorder that significantly affects patient quality of life (QoL). Patient-reported outcome measures (PROMs) can capture health outcomes from a patient’s perspective. The identification of PROMs used in adult patients with hemophilia (PwHs) can improve our understanding of patient care needs.
Objective:To examine the current use of PROMs in adult PwHs, evaluate the frequency of PROMs, and summarize the main evaluation dimensions and descriptive data of the included publications.
Methods:In this scoping review, PubMed, EMBASE, The Cochrane Library, Web of Science, Scopus, and EBSCO were searched from January 2000 to June 2023. This review focused on descriptions of the use of PROMs in adult PwHs. The search strategy followed the PRISMA-ScR guidelines.
Results:Of 32 934 sources identified, 394 articles including 56028 patients were included. A wide range of measures was available, and many were used only once. One hundred and fifty-four different PROMs were identified. The most commonly used generic PROMs were the EuroQoL Five-Dimensional Questionnaire (EQ-5D) (n=105, 26.6 %) and the 36-item Short Form General Health Survey (SF-36) (n=95, 24.1 %). The most commonly used hemophilia-specific PROM was the Hemophilia-specific health-related QoL questionnaire (A36 Hemofilia-QoL) (n=15, 3.8 %). However, psychological health has rarely been separately assessed.
Conclusion:This study provides a valuable summary of PROMs to facilitate research on hemophilia. Disease-specific instruments should be used more frequently to capture changes in patients, and psychological health should be considered in future studies.
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
7.U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research.,U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes. 2006; 4(79) https://doi.org/10.1186/1477-7525-4-79 |
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
|
| [45] |
|
| [46] |
|
| [47] |
|
| [48] |
|
| [49] |
|
| [50] |
|
| [51] |
|
| [52] |
|
| [53] |
|
| [54] |
|
| [55] |
|
| [56] |
|
| [57] |
|
| [58] |
|
| [59] |
|
| [60] |
|
| [61] |
|
| [62] |
|
| [63] |
|
| [64] |
|
| [65] |
|
| [66] |
|
| [67] |
|
| [68] |
|
| [69] |
|
| [70] |
|
| [71] |
|
| [72] |
|
| [73] |
|
| [74] |
|
| [75] |
|
| [76] |
|
| [77] |
|
| [78] |
|
| [79] |
|
| [80] |
|
| [81] |
|
| [82] |
|
| [83] |
|
| [84] |
|
| [85] |
|
| [86] |
|
| [87] |
|
| [88] |
|
| [89] |
|
/
| 〈 |
|
〉 |